This ExpertREACT article was originally published on 24 September 2008. Epidemiological data and pipeline positions described reflect the state of knowledge at that date.
The most infectious gastroenteritis pathogen
Noroviruses (NVs), members of the Caliciviridae family and previously called "Norwalk-like viruses" after the first isolated strain in 1972, are among the most highly infectious viruses known. They are environmentally stable - resistant to chlorination and heating to 60°C - and can remain viable for several weeks despite infection control measures. Noroviruses are the leading cause of epidemic acute gastroenteritis (AGE), responsible for approximately 50% of all foodborne gastroenteritis outbreaks in the US according to the CDC. In hospitals, norovirus outbreaks were particularly difficult to control, with attack rates of 30-60% among both patients and staff. Commercial cruise ships and military naval vessels were also severely affected.
In the US - which had no active national norovirus surveillance at the time of writing - norovirus infections were estimated to account for 235,000 clinic visits, 91,000 emergency room visits and 23,000 hospitalisations annually in children under five years. These figures were approximately half those attributable to rotavirus - another major cause of acute gastroenteritis in children - suggesting norovirus was a substantial but systematically under-recognised burden. In most healthy community-dwelling individuals norovirus caused a self-limiting mild illness resolving in 1-3 days. However, in elderly nursing home residents and immunocompromised patients, severe outcomes and death were recorded, and the sheer volume of cases placed enormous demand on healthcare systems during outbreak conditions.
The case for a vaccine: building evidence
VacZine Analytics reviewed the nascent norovirus vaccine field, where early-stage VLP (virus-like particle)-based approaches were showing immunogenicity in Phase I studies. The case for a norovirus vaccine was built on cumulative evidence of growing outbreak magnitude and frequency in healthcare settings - potentially worsened by improved diagnostic detection - and the recognition that current infection control measures alone were insufficient. The greatest commercial opportunity was likely in healthcare settings (long-term care, hospitals) and potentially in military or maritime deployments where operational readiness was impaired. However, VacZine Analytics noted that demonstrating protective efficacy in heterogeneous outbreak settings posed significant clinical trial design challenges, given the diversity of norovirus strains and the limited durability of natural immunity.